Artiva Biotherapeutics, Inc. Common Stock (ARTV)vsRevolution Medicines Inc (RVMD)
ARTV
Artiva Biotherapeutics, Inc. Common Stock
$11.27
-2.68%
HEALTHCARE · Cap: $563.14M
RVMD
Revolution Medicines Inc
$205.15
+3.71%
HEALTHCARE · Cap: $39.87B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
ARTV
Avoid20
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARTV
The strongest argument for ARTV centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ARTV
The primary concerns for ARTV are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
ARTV carries more volatility with a beta of 2.18 — expect wider price swings.
RVMD is growing revenue faster at -95.2% — sustainability is the question.
ARTV generates stronger free cash flow (-21M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 20/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artiva Biotherapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a promising pipeline targeting both hematologic and solid tumors, the company is at the forefront of innovation in the dynamic field of immuno-oncology. Leveraging its commitment to scientific excellence and strategic collaborations, Artiva is strategically positioned to advance its clinical candidates, thereby significantly improving patient outcomes in the fight against cancer. As it progresses through crucial clinical trials, the company's innovative approach holds the potential to reshape cancer treatment paradigms.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?